Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05176717 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)
A Phase 2 study, sponsored by Laboratoires Thea.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT05176717: Clinical Trial Phase 2 study, sponsored by Laboratoires Thea.
NCT05176717 is a Phase 2 study that was terminated before completion, run by Laboratoires Thea. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05176717, a Phase 2 study, was terminated before completion, sponsored by Laboratoires Thea.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene with early to moderate vision loss.
Primary Outcome
Change from baseline in mean sensitivity (based on static perimetry) at 12 months of treatment versus sham-procedure
Interventions
- DRUG QR-421a
- OTHER Sham-procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2022-08-02 |
| Phase | Phase 2 |
Why NCT05176717 stopped before completion
NCT05176717 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which QR-421a is the first listed.
NCT05176717 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05176717 about?
NCT05176717 is a clinical study titled "Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)". The purpose of this study is to evaluate the efficacy safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene with early to moderate vision loss.
What is the current status of trial NCT05176717?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2021-12-15. Estimated completion is 2022-08-02.
What interventions are being tested in trial NCT05176717?
The interventions under investigation include: QR-421a (DRUG), Sham-procedure (OTHER).
Who is sponsoring clinical trial NCT05176717?
This trial is sponsored by Laboratoires Thea, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05176717's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI